Compounded vs. Brand-Name Semaglutide: An Honest Comparison

Almost every GLP-1 conversation in 2026 still starts with the same question: is the compounded version the same as the brand?

The honest answer is: no, but not in the way most people assume. Here's what's actually different, what the FDA rules are now that the shortage has ended, and how I think about the choice.

---

The two products

Brand-name semaglutide (Ozempic, Wegovy, Rybelsus) is manufactured by Novo Nordisk under FDA approval. Every pen is identical: same active ingredient, same concentration, same excipients, same expiration testing, same labeling.

Compounded semaglutide is mixed by a licensed compounding pharmacy — either a 503A pharmacy (patient-specific) or a 503B outsourcing facility (batch, FDA-registered but not FDA-approved). The active ingredient is sourced from an FDA-registered API supplier. The pharmacy combines it with a sterile carrier, sometimes with additional ingredients like B12 or glycine.

Both can be safe. They are not the same product.

---

What changed when the shortage ended

From 2022 through late 2024, semaglutide was on the FDA shortage list. Under section 503A and 503B of the FD&C Act, that allowed pharmacies to compound it more freely.

In late 2024 the FDA declared the shortage resolved. The compliance picture now:

• Plain semaglutide, mass-compounded for telehealth marketing, is no longer permitted.
• Patient-specific compounding under 503A is still legal when there is a documented clinical reason — typically a dose not commercially available, an allergy or intolerance to an inactive ingredient, or a personalized combination (semaglutide + B12, for example).
• Reputable pharmacies have shifted to these personalized formulations. Sketchy operations have not, and that is a meaningful signal.

If a clinic is still selling plain compounded semaglutide as a flat monthly subscription with no clinical individualization, that is worth questioning.

---

Where the real differences live

Cost. Compounded is meaningfully cheaper — often $200–$400/month versus $1,000–$1,400 for brand without insurance coverage. For patients paying cash, this is not a small difference.

Dose flexibility. Brand pens come in fixed dose steps. Compounded vials allow finer titration, which can matter for patients who are very sensitive to side effects or who plateau between standard steps.

Supply chain transparency. Brand: one manufacturer, one quality system. Compounded: the pharmacy's API supplier matters, their sterility testing matters, their beyond-use dating matters. A good compounding pharmacy will tell you who their API supplier is and share their certificates of analysis. I only work with pharmacies that do.

If something goes wrong. Brand product has a clear adverse-event reporting pathway and manufacturer liability. Compounded sits in a more complicated space. This is not theoretical — it is the single biggest reason I are picky about which pharmacies I use.

What's actually in it. Independent testing in 2023–2024 found that some compounded products contained semaglutide salts (sodium or acetate) rather than the base molecule studied in trials. I require base semaglutide from my pharmacy partners and verify it.

---

How I decide, patient by patient

I prescribe brand-name when:

• Insurance covers it (always run this first).
• The patient is at a stable maintenance dose that matches a commercial pen.
• There is any history that makes provenance especially important — pregnancy planning, transplant medications, complicated allergies.

I prescribe compounded when:

• Cost is the difference between staying on therapy and stopping.
• The patient needs a dose that doesn't exist commercially (micro-doses for tolerance, fractional steps between 1.0 and 1.7 mg).
• There is a clinical reason for a personalized formulation (B12 in patients with low B12, for instance).

In both cases the medical workup, the dosing strategy, the follow-up cadence, and the safety monitoring are identical. The molecule is one part of the program.

---

Questions to ask before you start

• Is this a 503A or 503B pharmacy? Are they licensed in my state?
• What is the API source and do you have a current certificate of analysis?
• Is the product semaglutide base, or a salt form?
• What is the beyond-use date on my vial and how should it be stored?
• Who is my prescribing clinician and how do I reach them if something happens?

If a telehealth platform can't answer these in plain language, that's the answer.

---

The honest bottom line

Brand-name is the studied product. Compounded, done right, is a reasonable cash-pay alternative with real tradeoffs. Done poorly, it is the wild west.

The medication is the smaller part of the work. The bigger part is the dosing plan, the protein and movement strategy, the follow-up, and the off-ramp when you get to your goal. That part doesn't change with the brand on the vial.